DATROWAY® (datopotamab deruxtecan) is achieving significant tumor responses when combined with immunotherapies in early and advanced non-small cell lung cancer (NSCLC) patients, according to recent clinical trial results presented at the 2025 American Society of Clinical Oncology Annual Meeting.
Phase 1b Trials Highlight Combination Therapies
In the TROPION-Lung02 and TROPION-Lung04 phase 1b trials, DATROWAY combined with Merck’s KEYTRUDA® (pembrolizumab) and platinum-based chemotherapy demonstrated objective response rates exceeding 54% in advanced NSCLC patients. These combinations were well-tolerated, with manageable adverse events, supporting their potential as first-line treatments. Additionally, exploratory analyses indicated that higher TROP2 expression levels might predict better patient outcomes, suggesting a pathway for personalized therapy approaches.
NeoCOAST-2 Shows Promise in Neoadjuvant Setting
The NeoCOAST-2 phase 2 trial revealed that DATROWAY, when paired with durvalumab and single-agent platinum chemotherapy, achieved a major pathologic response rate of 63% in patients with resectable early-stage NSCLC. These findings indicate the combination’s effectiveness in reducing tumor burden before surgery, potentially improving long-term survival rates. The safety profile remained consistent, ensuring that treatment did not impede surgical feasibility.
- DATROWAY plus KEYTRUDA showed over 54% objective response in advanced NSCLC.
- Higher TROP2 expression correlates with prolonged progression-free survival.
- Neoadjuvant DATROWAY combinations achieved a 63% major pathologic response.
- Safety profiles across trials remained consistent with known side effects.
The integration of DATROWAY into various treatment regimens underscores its versatility and potential to enhance therapeutic outcomes for NSCLC patients. As ongoing trials continue to evaluate its efficacy and safety in larger populations, DATROWAY is positioned to become a cornerstone in NSCLC management strategies.
With over 30 clinical trials underway, Daiichi Sankyo and AstraZeneca are committed to expanding the applications of DATROWAY across multiple cancer types. The promising results in NSCLC add to its growing profile, highlighting the collaborative efforts to address unmet medical needs and improve patient survival rates.
Patients and healthcare providers can anticipate more comprehensive data in the coming months, which will further clarify the role of DATROWAY in cancer therapy. Its ability to target TROP2 extensively opens new avenues for treatment personalization, potentially leading to more effective and tailored cancer care solutions.
DATROWAY’s advancements represent a significant stride in NSCLC treatment, offering hope to patients with limited options and setting the stage for future innovations in oncology.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
